Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Neurogene (NGNE) EBITDA (2018 - 2025)

Neurogene (NGNE) has disclosed EBITDA for 5 consecutive years, with -$23.8 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, EBITDA fell 7.29% year-over-year to -$23.8 million, compared with a TTM value of -$97.3 million through Sep 2025, down 53.62%, and an annual FY2024 reading of -$82.6 million, down 48.62% over the prior year.
  • EBITDA was -$23.8 million for Q3 2025 at Neurogene, up from -$26.1 million in the prior quarter.
  • Across five years, EBITDA topped out at -$18.8 million in Q1 2024 and bottomed at -$26.1 million in Q2 2025.